# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

> **NCT05384262** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 183 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** AZD0780
- **DRUG:** AZD0780
- **DRUG:** AZD0780
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT05384262
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-18
- **Primary completion:** 2024-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2024-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05384262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05384262, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05384262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*